Navigation Links
Vandetanib in thyroid cancer: Added benefit not proven
Date:8/2/2013

Vandetanib (trade name: Caprelsa) has been approved in Germany since February 2012 for the treatment of adult patients who have a particular form of aggressive thyroid cancer. In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG).

There is a hint that pain occurs later or gets worse later in a part of the patients, the ones aged under 65 years.But because of the overall poor data on side effects, no conclusion could be drawn about harm. Therefore it was not possible to balance positive and negative effects. Overall, an added benefit of vandetanib is therefore not proven.

Contents of the first dossier on vandetanib were incomplete

Vandetanib underwent a first early benefit assessment procedure in 2012. In this procedure, the drug manufacturer did not present any data for the patients for whom the drug is approved. The added benefit was regarded as not proven because the contents of the dossier were incomplete. The pharmaceutical company could apply for a reassessment of vandetanib within a transition period and submit a new dossier to the Federal Joint Committee (G-BA).

"Best supportive care" as the appropriate comparator therapy

In the newly submitted dossier, the company now presented an analysis of data for patients who were treated according to the approval status. As specified by the G-BA, vandetanib was compared with "best supportive care". This means the best possible supportive therapy, optimized for the individual patient for alleviation of symptoms and improvement in the quality of life.

The only study relevant for the benefit assessment, the approval study, compared the administration of vandetanib in combination with "best supportive care" with a treatment consisting of "best supportive care" in combination with
'/>"/>

Contact: Press Contact
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Vandetanib in thyroid cancer: No proof of added benefit
2. Thyroid Condition Linked to Heart Problems: Study
3. Lower-Dose Radioiodine Effective Against Thyroid Cancer
4. Staging and risk stratification of thyroid cancer improved with SPECT/CT
5. Obese More Likely to Be Diagnosed With Advanced Thyroid Cancer
6. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
7. Hyperthyroidism linked to increased risk of hospitalization for heart and blood-vessel disease
8. Gene expression test identifies low-risk thyroid nodules
9. Detecting thyroid disease by computer
10. Experts issue recommendations for treating thyroid dysfunction during and after pregnancy
11. Drug May Aid People With Advanced Thyroid Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... ... entitled "Applying Data To Reduce Hospital Readmissions." , The Centers for Medicare and ... facility-level data used as part of their penalty calculation. Known as the QualityNet ...
(Date:7/27/2015)... ... July 27, 2015 , ... At Champagne Smiles, they know that ... loss can incur a lot of stress, pain, discomfort and embarrassment, which is why ... All-On-4™ treatment reaps the benefits of implants with the cost savings of dentures for ...
(Date:7/27/2015)... ... , ... According to an article published by the Times Free Press ... stemming from intravenous drug use. Intravenous drug use causes more overdoses and is responsible ... including Hepatitis B and C and HIV. Drug treatment facilities in Tennessee have witnessed ...
(Date:7/27/2015)... (PRWEB) , ... July 27, 2015 , ... ... of fullerenes in medical and diagnostics applications is rapidly increasing and is driven ... and cancer treatment, they are increasingly being evaluated for use in bio implants. ...
(Date:7/27/2015)... ... ... Sher Fertility Institute, a national network of fertility clinics known ... their clinical team in Las Vegas. , Dr. Mark Severino joins ... Endocrinology teams in the region. , Combined Drs. Sher and Severino have more than ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 2Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 3Health News:NJ Top Dentists Presents, Dr. Richard Champagne of Champagne Smiles! 4Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 3Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:Dr. Mark Severino Joins Dr. Geoffrey Sher at Sher Fertility Las Vegas- Sher Fertility is National Network of Fertility Clinics Known for Exceptional Patient Care 2Health News:Dr. Mark Severino Joins Dr. Geoffrey Sher at Sher Fertility Las Vegas- Sher Fertility is National Network of Fertility Clinics Known for Exceptional Patient Care 3
... the risk of developing breast cancer, says a new ... between handedness// and incidence of breast cancer in over ... 1941, reports science portal EurekAlert. ,They recorded ... economic status, smoking habits, family history of breast cancer, ...
... Wake Forest University Baptist Medical Center have begun a ... synthetic steroids to prevent premature babies//., ,Premature infants ... fully developed. Currently the best treatments are to give ... for as long as possible. ,Sheep will ...
... designed a plastic device which helps in prevention of ... patients//. The scarring in these cancer patients hinders the ... to reduce the risk of scarring in women undergoing ... ,Joan Thomas, is Macmillan Nurse specialist who has ...
... chemicals has been known to be associated with health ... But it is known not until recently that rheumatoid ... to mineraloil., ,The exact causative factor rheumatiod factor ... and environmental fcators have been help responsible to a ...
... might help lower the negative impact on a person's blood ... that job strain had a significant impact, both clinically and ... low marital cohesion, or a lack of support from a ... of blood pressure over one year. High marital cohesion in ...
... to lose the excess weight that one has to carry like ... best way is that adopted earlier that is the basic principle ... Obesity is a big problem these days., ,Calorie counting ... towards weight control., ,With so many dietary plans jostling for ...
Cached Medicine News:
(Date:7/27/2015)... 20, 2015 Research and ... the "Global Pressure Relief Devices Market 2015-2019" ... Relief Devices market to grow at a CAGR of ... Pressure Relief Devices Market 2015-2019, has been prepared based ... experts. The report covers the Americas, and the APAC ...
(Date:7/27/2015)... 27, 2015  Attorney Advertising-- Bronstein, Gewirtz & Grossman, ... purchasers of the securities of AMAG Pharmaceuticals Inc. ... investors are advised to contact Peretz Bronstein ... Kimelman at info@bgandg.com or 212-697-6484. ... certain of its officers and/or directors have violated ...
(Date:7/27/2015)... , July 20, 2015 Research and Markets ... "Medical Device Regulation in Asia/Pacific Markets Seminar" ... the European Medical Device market is well established, the ... China , together with other countries ... the process of implementing, their own medical device regulations. ...
Breaking Medicine Technology:Global Pressure Relief Devices Market 2015-2019 with ArjoHuntleigh, Hill-Rom, Paramount Bed Holdings & Stryker Dominating 2SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of AMAG Pharmaceuticals Inc. 2Medical Device Regulation in Asia/Pacific Markets Seminar: London, UK - 21st, 22nd of September 2015 2
... Myocor, Inc. announced that,the U.S. Food and ... Valvular and Ventricular Improvement Via iCoapsys Delivery ... evaluate the,safety and feasibility of the percutaneously ... valve insufficiency caused by left,ventricular dysfunction and ...
... Senesco,Technologies, Inc. ("Senesco" or the "Company") (Amex: ... lab studies at Mayo Clinic focused,on multiple myeloma. ... Factor 5A gene technology to up-regulate apoptosis of ... for,encapsulation of Factor 5A to enhance the time ...
Cached Medicine Technology:Myocor Receives Approval for Percutaneous Trial 2Senesco Technologies Initiates Preclinical Studies for Cancer Target 2
Full plate covers seal all 24 MicroAmp tubes...
Omniseal TD mat. Reusable rubber mat for sealing PCR plates. 5 pk....
Inquire...
... A soft, heat-resistant, aluminum foil film ... AlumaSeal II minimizes evaportaion and vapor ... need for heat-sealing devices or mats. ... sovents and reagents. Compared to other ...
Medicine Products: